Brief: Genmab H1 Operating Profit Rises To $548 Mln
07/08/2025 16:22
Aug 8 (Reuters) - Genmab A/S GMAB.CO: GENMAB REVENUE INCREASED19% COMPARED TO FIRST SIX MONTHS OF 2024, TO $1,640 MILLION OPERATING PROFIT INCREASED TO $548 MILLION IN H1 2025 DARZALEX SALES UP 22% TO $6,776 MILLION IN H1 2025 UPDATES 2025 GUIDANCE DUE TO DARZALEX ROYALTIES 2025 FY OUTLOOK OPERATING PROFIT $1,055 - $1,405 REVISED 2025 FY 3,500 USD MILLION - 3,700 USD MILLION Source text: ID:nGNE5V8BjK Further company coverage: GMAB.CO (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss